Sunday November 19th 2017

Teriflunomide in multiple sclerosis: added benefit not proven

Regarding side effects, there are both positive and negative effects in comparison with beta interferon 1aTeriflunomide (trade name: Aubagio) has been approved in Germany since August 2013 for adults with relapsing remitting multiple sclerosis.

Link to original – 

Teriflunomide in multiple sclerosis: added benefit not proven

Leave a Comment

More from category

Gut bacteria at young age can contribute to MS disease onset and progression, study suggests
Gut bacteria at young age can contribute to MS disease onset and progression, study suggests

Researchers at Rutgers Robert Wood Johnson Medical School published a study suggesting that gut bacteria at young age [Read More]

Age and gut bacteria contribute to MS disease progression, according to Rutgers
Age and gut bacteria contribute to MS disease progression, according to Rutgers

(Rutgers University) Gut bacteria at a young age can contribute to multiple sclerosis disease onset and progression. [Read More]

Virtual reality training may be effective alternative to standard therapy after stroke
Virtual reality training may be effective alternative to standard therapy after stroke

Using virtual reality therapy to improve arm and hand movement after a stroke is equally as effective as regular [Read More]

Social care failing people with disabilities, says leading charity
Social care failing people with disabilities, says leading charity

Young people with MS forced to live in care homes for older people Related items fromOnMedica Social care set to eat up [Read More]

World’s Largest MS Research Conference Features Advances in Progressive MS, Myelin Repair, Lifestyle
World’s Largest MS Research Conference Features Advances in Progressive MS, Myelin Repair, Lifestyle

/About-the-Society/News/World’s-Largest-MS-Research-Conference-Features-Ad [Read More]